Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 14;14(1):98.
doi: 10.1007/s12672-023-00658-7.

Modern treatment strategies in pediatric oncology and hematology

Affiliations
Review

Modern treatment strategies in pediatric oncology and hematology

Katarzyna Adamczewska-Wawrzynowicz et al. Discov Oncol. .

Abstract

Every year, approximately 400 00 children worldwide are diagnosed with cancer. Although treatment results in most types of childhood neoplasms are excellent with survival more than 80%, there are some with poor prognosis. Also recurrent and resistant to treatment childhood cancer remain a therapeutic challenge. Besides chemotherapy, which has been the basis of cancer therapy for years, molecular methods and precisely targeted therapies have recently found their usage. As a result of that, survival has improved and has positively impacted the rate of toxicities associated with chemotherapy (Butler et al. in CA Cancer J Clin 71:315-332, 2021). These achievements have contributed to better quality of patients' lives. Current methods of treatment and ongoing trials give hope for patients with relapses and resistance to conventional chemotherapy. This review focuses on the most recent progress in pediatric oncology treatments and discusses specific therapy methods for particular cancers types of cancer. Targeted therapies and molecular approaches have become more beneficial but research need to be continued in this field. Despite significant breakthroughs in pediatric oncology in the last few years, there is still a need to find new and more specific methods of treatment to increase the survival of children with cancer.

Keywords: Immunotherapy; Neoplasm; Pediatric oncology; Targeted therapy; Treatment.

PubMed Disclaimer

Conflict of interest statement

Not applicable.

Figures

Fig. 1
Fig. 1
Distribution (%) of pediatric cancers (0–14 years)
Fig. 2
Fig. 2
Distribution (%) of pediatric cancers (15–19 years)
Fig. 3
Fig. 3
Five year overall survival rates of pediatric cancers (0–19 years)

Similar articles

Cited by

References

    1. Butler E, Ludwig K, Pacenta HL, Klesse LJ, Watt TC, Laetsch TW. Recent progress in the treatment of cancer in children. CA Cancer J Clin. 2021;71(4):315–332. doi: 10.3322/CAAC.21665.E. - DOI - PubMed
    1. Steliarova-Foucher E, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18(6):719–731. doi: 10.1016/S1470-2045(17)30186-9/ATTACHMENT/D5279E92-7174-4FDA-9099-C998E708047B/MMC1.PDF. - DOI - PMC - PubMed
    1. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524–2539. doi: 10.3324/HAEMATOL.2020.247031. - DOI - PMC - PubMed
    1. Cerchione C, Locatelli F, Martinelli G. Dasatinib in the management of pediatric patients with philadelphia chromosome-positive acute lymphoblastic leukemia, front. Oncol. 2021;11:830. doi: 10.3389/fonc.2021.632231. - DOI - PMC - PubMed
    1. Rossoff J, et al. Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol. 2020;189:363–368. doi: 10.1111/bjh.16338. - DOI - PubMed

LinkOut - more resources